1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with olmesartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K | 1 |
| Higashi, K; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Oshima, N; Sakurai, Y; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
2 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and olmesartan
| Article | Year |
|---|---|
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Enzyme Inhibitors; Glycated Hemoglobin; Imidazoles; Intracellular Signaling Peptides and Proteins; Kidney; Lipid Metabolism; Male; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Rats; Rats, Inbred OLETF; Rho Factor; rho-Associated Kinases; Signal Transduction; Tetrazoles | 2007 |
Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Enzyme Inhibitors; Hypercholesterolemia; Imidazoles; Kidney Glomerulus; Lectins, C-Type; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Membrane Proteins; Microscopy, Electron; Phenotype; Proteinuria; Rats; Receptors, Cell Surface; Renal Insufficiency, Chronic; rho-Associated Kinases; RNA, Messenger; Tetrazoles | 2013 |